• Ivan Urits, Kyle Gress, Karina Charipova, Kelly Habib, David Lee, Christopher Lee, Jai Won Jung, Hisham Kassem, Elyse Cornett, Antonella Paladini, Giustino Varrassi, Alan D Kaye, and Omar Viswanath.
• Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: iurits@bidmc.harvard.edu.
• Best Pract Res Clin Anaesthesiol. 2020 Sep 1; 34 (3): 463-477.

AbstractChronic pain can be recurrent or constant pain that lasts for longer than 3 months and can result in disability, suffering, and a physical disturbance. Related to the complex nature of chronic pain, treatments have a pharmacological and non-pharmacological approach. Due to the opioid epidemic, alternative therapies have been introduced, and components of the plant Cannabis Sativa, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have gained recent interest as a choice of treatment. The exact mechanism for CBD is currently unknown, but unlike the CBD's psychoactive counterpart, THC, the side effects of CBD itself have been shown to be overall much more benign. The current pharmaceutical products for the treatment of chronic pain are known as nabiximols, and they contain a ratio of THC combined with CBD, which has been promising. This review focuses on the treatment efficacy of CBD, THC: CBD-based treatments for chronic pain and adverse events with each.Copyright © 2020. Published by Elsevier Ltd.

19 keywords...

hide…